Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Clinical Trials
10
0 active
Approvals
17
Total approvals
Agencies
2
Regulatory bodies
Founded
N/A
Completed
10
100.0%
- Journey Medical Corporation reported total revenues of $18.5 million for the second quarter of 2026, a 23% increase from $15.0 million in the prior-year quarter. - Emrosi generated $8.1 million in revenue during the quarter, with total prescriptions rising to approximately 36,000, up from 30,000 in Q1 2026 and 27,000 in Q4 2025. - GAAP net loss narrowed to $0.3 million, or $(0.01) per share, compared to a net loss of $3.8 million, or $(0.16) per share, in the second quarter of 2025. - The company held $25.6 million in cash and cash equivalents as of June 30, 2026, positioning it to advance its dermatology strategy toward profitability.
- Journey Medical Corporation announced positive Phase 1 clinical trial results for Emrosi (low-dose minocycline) published in the Journal of Drugs in Dermatology, demonstrating the treatment met all three primary objectives with no significant safety issues. - The 16-week study of 60 healthy adults showed no detectable effects on skin, gastrointestinal tract, or vaginal microflora, with no development of antibiotic resistance to minocycline. - Emrosi is FDA-approved for treating inflammatory lesions of rosacea in adults, a condition affecting over 16 million Americans and 415 million people worldwide. - The results support Emrosi's potential for long-term use as a therapeutic option for moderate-to-severe rosacea without meaningfully disrupting normal microbiota.
- Fortress Biotech achieved a 20.5% increase in net revenue to $17.6 million in Q3 2025, driven by strong performance from its dermatology products portfolio. - The company completed strategic exits with Sun Pharma acquiring Checkpoint Therapeutics for ~$28 million upfront to Fortress, plus potential additional payments and royalties. - Dotinurad, a next-generation URAT1 inhibitor for gout treatment, advanced into two Phase 3 trials following Crystalys Therapeutics' $205 million Series A financing. - Journey Medical's rosacea treatment Emrosi demonstrated statistical superiority over existing therapies in pooled Phase 3 analysis, with expanded payer coverage reaching over 100 million lives.
- Journey Medical's Emrosi (DFD-29) achieved 62.7% IGA treatment success compared to 39.0% for Oracea and 28.2% for placebo in combined Phase 3 trials (p<0.001). - The modified-release minocycline formulation reduced inflammatory lesions by 19.2 on average versus 14.8 for Oracea and 11.3 for placebo over 16 weeks. - The drug demonstrated a favorable safety profile with no major safety issues or serious adverse events related to the study drug in 653 patients. - Results were presented at the 2025 Fall Clinical Dermatology Conference, reinforcing Emrosi's potential as a standard of care for rosacea treatment.
- Fortress Biotech secured FDA approvals for two key products in Q4 2024: Emrosi for inflammatory lesions of rosacea and UNLOXCYT for advanced cutaneous squamous cell carcinoma, with commercial launch of Emrosi already underway. - Subsidiary Checkpoint Therapeutics is being acquired by Sun Pharma in a deal valued at $4.10 per share plus potential CVR of $0.70, expected to generate approximately $28 million for Fortress plus a 2.5% royalty on UNLOXCYT sales. - FDA accepted New Drug Application for CUTX-101 for priority review with PDUFA date of September 30, 2025, potentially qualifying for a valuable Priority Review Voucher upon approval.
- The FDA has approved Emrosi (minocycline hydrochloride) as a 40mg extended-release capsule for treating inflammatory lesions of rosacea in adults. - Emrosi demonstrated statistically significant superiority over Oracea and placebo in Phase 3 trials, showing success in Investigator’s Global Assessment and lesion reduction. - Journey Medical anticipates launching Emrosi in early 2025, positioning it as a potential best-in-class oral medication for rosacea with a favorable safety profile. - Emrosi's extended-release formulation delivers minocycline steadily, mitigating drug level fluctuations and improving tolerability for patients with rosacea.
- The FDA has approved Emrosi™ (minocycline hydrochloride extended-release capsules, 40 mg) for treating inflammatory lesions of rosacea in adults. - Journey Medical anticipates launching Emrosi™ in late Q1 or early Q2 of 2025, expanding their dermatology-focused product portfolio. - Clinical data presented at the 44th Fall Clinical Dermatology Conference highlighted Emrosi's higher dermal concentration compared to doxycycline. - The approval marks a significant advancement in rosacea treatment, addressing a prevalent dermatological condition.
- The FDA approved Emrosi (minocycline hydrochloride extended-release capsules, 40mg) for treating inflammatory lesions of rosacea in adults, marking Fortress Biotech's first FDA approval. - Clinical data presented at the Fall Clinical Dermatology Conference showed Emrosi provides higher dermal concentration than doxycycline, potentially leading to clinically meaningful impact. - Fortress Biotech anticipates a PDUFA goal date of December 28, 2024, for cosibelimab, an anti-PD-L1 antibody, for treating metastatic or locally advanced cutaneous squamous cell carcinoma. - Journey Medical will launch Emrosi in late Q1 or early Q2 2025, offering a potential new treatment paradigm for millions suffering from rosacea.
- Fortress Biotech announced FDA approval for Emrosi (minocycline hydrochloride) for treating inflammatory lesions of rosacea in adults, marking their first FDA approval. - The PDUFA goal date for cosibelimab, an anti-PD-L1 antibody, is set for December 28, 2024, targeting metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC). - Clinical data presented at the Fall Clinical Dermatology Conference showed Emrosi has higher dermal concentration than oral doxycycline for rosacea treatment. - Longer-term data from the pivotal trial of cosibelimab in cSCC demonstrated deepening responses over time, with higher objective and complete response rates.
- Journey Medical's Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) has been approved by the FDA for treating inflammatory lesions of rosacea in adults. - The launch of Emrosi is anticipated in late Q1 or early Q2 of 2025, following the completion of manufacturing activities and deployment of the dermatology sales force. - Clinical data presented at a recent conference highlighted Emrosi's higher dermal concentration compared to oral Doxycycline, potentially leading to clinically meaningful impact. - Journey Medical reported $14.6 million in total revenues for Q3 2024, with a focus on commercializing core dermatology products and preparing for the launch of Emrosi.
